The emerging interest and requests for biomarker testing for colon cancer has led to a shift away from a one-size-fits-all approach and towards a precision-based methodology to optimize patient care and patient outcomes. Biomarkers are becoming standard practice in guiding targeted and conventional therapies for patients with CRC and advancing personalized care for improved clinical outcomes. In this expert brief, Dr. Sharlene Gill and Dr. Brandon Sheffield address the collaborative role of the pathologist and oncologist in facilitating timely biomarker testing and discuss the use of biomarkers to optimize metastatic colorectal cancer care.
This program has received an educational grant or in-kind support from Amgen Canada.